Huang, Yangyun Zhu, Lihuan Guo, Tianxing Chen, Wenshu Zhang, Zhenlong Li, Wujin Pan, Xiaojie
Published in
Human vaccines & immunotherapeutics
Programmed cell death protein 1 (PD-1) inhibitors are the first-line treatment for advanced non-small-cell lung cancer (NSCLC) patients. However, their efficacy in metastatic NSCLC patients remains controversial. The aim of our study was to evaluate the prognosis of advanced metastatic NSCLC patients treated with PD-1 inhibitors, and discuss the pr...
Succaria, Farah Kvistborg, Pia Stein, Julie E Engle, Elizabeth L McMiller, Tracee L Rooper, Lisa M Thompson, Elizabeth Berger, Alan E van den Brekel, Michiel Zuur, Charlotte L
...
Published in
Cancer immunology, immunotherapy : CII
Approximately 15% of advanced head and neck squamous cell carcinomas (HNSCC) respond to anti-PD-(L)1 monotherapies. Tumor PD-L1 expression and human papillomavirus (HPV) status have been proposed as biomarkers to identify patients likely to benefit from these treatments. We aimed to understand the potential immune effects of HPV in HNSCC and to cha...
Zhou, Xuebing Ding, Xiaoling Li, Hai Yang, Chun Ma, Zhanbing Xu, Guangxian Yang, Shaoqi Zhang, Dong Xie, Xiaoliang Xin, Lei
...
Published in
Immunological investigations
Background: The role of T cell Ig and ITIM domain (TIGIT) and programmed cell death-1 (PD-1) in colorectal cancer (CRC) with mismatch repair deficiency is unknown.Methods: This was a study of 60 CRC patients with mismatch repair deficiency and 30 healthy controls between June 2015 and October 2015.Results: The expression of Foxp3, PD-1, and TIGIT w...
McGehee, Elizabeth Patel, Hetalkumari Pearson, Caroline Clements, Keri Jaso, Jesse Manuel Chen, Weina Callan, Alexandra Desai, Neil Ramakrishnan Geethakumari, Praveen
Published in
Journal of Medical Case Reports
BackgroundExtranodal natural killer/T-cell lymphoma is a rare, aggressive non-Hodgkin lymphoma that is treated upfront mostly with L-asparaginase containing regimens. Relapsed extranodal natural killer/T-cell lymphoma is associated with a poor prognosis, and there is no established standard of care.Case presentationWe report the case of a 72 year-o...
Tian, Chia-Yi Ou, Yang-Hao Chang, Shih-Liang Lin, Chih-Ming
Published in
Journal of Medical Case Reports
IntroductionPembrolizumab and other immune checkpoint inhibitors are the emerging treatment for selected, high-grade malignancies. However, a small number of patients are unable to tolerate its adverse effects, leading to discontinuation of this potentially life-changing therapy. In this study, we present a case of high-grade urothelial carcinoma p...
Fanale, Daniele Incorvaia, Lorena Badalamenti, Giuseppe De Luca, Ida Algeri, Laura Bonasera, Annalisa Corsini, Lidia Rita Brando, Chiara Russo, Antonio Iovanna, Juan Lucio
...
Published in
Cancers
Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstra...
Xiaohong, Chen Jianzhou, Zou Bo, Shen Wenlv, Lv Xuesen, Cao Fangfang, Xiang
Published in
Canadian journal of physiology and pharmacology
The purpose of this study was to explore the differences between exhausted CD8+ T cells in hepatocellular carcinoma (HCC) patients with and without uremia. We enrolled 45 uremic patients who were recently diagnosed with HCC into the HCC + uremia cohort and similar patients with HCC but without uremia into the HCC-only cohort. Lymphocytes were obtai...
Nuytemans, Laure Sys, Gwen Creytens, David Lapeire, Lore
Published in
Acta clinica Belgica
Background: The prognosis and treatment of metastatic osteosarcoma have not changed in the last decades and the responses to chemotherapy in this setting are disappointing. In the past years, immunotherapy has found its place in the treatment of different tumor types. Its role in the treatment of sarcomas, and in particular osteosarcoma, is less cl...
Griewing, Luisa Maria Schweizer, Claudia Schubert, Philipp Rutzner, Sandra Eckstein, Markus Frey, Benjamin Haderlein, Marlen Weissmann, Thomas Semrau, Sabine Gostian, Antoniu-Oreste
...
Published in
BMC Cancer
BackgroundImmune checkpoint inhibitors (ICI) have become standard treatment in different tumor entities. However, safe treatment with ICI targeting the PD-1/PD-L1 axis requires early detection of immune-related adverse events (irAE). There exist different questionnaires of drug manufacturers for the detection of irAE that have not been validated so...
Pinato, David J. Cortellini, Alessio Sukumaran, Ajithkumar Cole, Tom Pai, Madhava Habib, Nagy Spalding, Duncan Sodergren, Mikael H. Martinez, Maria Dhillon, Tony
...
Published in
BMC Cancer
BackgroundAfter liver resection (LR), patients with hepatocellular cancer (HCC) are at high risk of recurrence. There are no approved anti-cancer therapies known to affect such risk, highlighting the acute need for novel systemic therapies to control the probability of disease relapse. Immunotherapy is expanding as a novel treatment option for HCC....
